Anti-angiogenic Therapy-Mediated Endothelial Damage: A Driver of Breast Cancer Recurrence?

Area of Science:

• Oncology
• Cancer Biology
• Translational Medicine

Background:

• Anti-angiogenic therapy was initially proposed as a universal cancer treatment targeting neovascularization to induce tumor dormancy.
• Preclinical studies in mouse models demonstrated significant inhibition of metastatic outgrowth, raising hopes for clinical efficacy.
• Despite decades of research, the translation of anti-angiogenic therapy's promise into improved overall survival in human patients, especially in breast cancer, has been disappointing.

Purpose of the Study:

• To critically evaluate the clinical efficacy of anti-angiogenic therapy in breast cancer.
• To investigate the reasons behind the limited success of anti-angiogenic agents in impacting overall survival.
• To explore potential avenues for improving the effectiveness of anti-angiogenic strategies in cancer treatment.

Main Methods:

• Review of clinical trial data for anti-angiogenic agents in early- and advanced-stage breast cancer.
• Analysis of progression-free survival and overall survival outcomes.
• Comparative assessment of preclinical findings versus clinical observations.

Main Results:

• Anti-angiogenic agents have shown limited ability to prolong overall survival in breast cancer patients, despite sometimes improving progression-free survival.
• The efficacy of these agents in suppressing overt metastases and preventing micrometastasis outgrowth in humans is restricted.
• A significant discrepancy exists between the promising results observed in preclinical models and the outcomes in clinical settings.

Conclusions:

• The clinical application of anti-angiogenic therapy, as currently implemented, has not met its initial expectations for indefinite tumor dormancy or significant overall survival benefits in breast cancer.
• The failure to translate preclinical success into clinical benefit suggests complex biological mechanisms that counteract anti-angiogenic effects in humans.
• There is a critical need to re-evaluate and refine anti-angiogenic strategies to overcome resistance and improve therapeutic outcomes in cancer patients.